782500-75-8

Basic information

• Product Name: Albiglutide
• Synonyms: albiglutide;Albugon;Naliglutide;7-36-Glucagon-like peptide I (8-glycine) (human), fusion protein with 7-36-glucagon-like peptide I (8-glycine) (human) fusion protein with serum;Gsk 716155;Unii-5E7U48495e;7-36-Glucagon-likepeptide I [8-glycine] (huMan), fusion protein with 7-36-glucagon-like peptide I[8-glycine] (huMan) fusion protein with seruM albuMin (huMan)
• CAS NO: 782500-75-8
• Molecular Formula: C148H223N39O46
• Molecular Weight: 3284.58792
• Product Categories: GLP
• Mol File: 782500-75-8.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Albiglutide(CAS DataBase Reference)
• NIST Chemistry Reference: Albiglutide(782500-75-8)
• EPA Substance Registry System: Albiglutide(782500-75-8)

Safety Data

• Hazardous Substances Data: 782500-75-8(Hazardous Substances Data)

Usage

Description

Albiglutide, also known as naliglutide or GSK 716155, is a fusion protein consisting of a sequential dimer of GLP-1(7–36)(Ala8→Gly) covalently linked to modified human serum albumin (HSA). It is currently in phase III clinical trials and, if marketed (under the name Syncria by GlaxoSmithKline), will be administered by injection with a half-life and duration of 6 to 7 days, allowing for weekly administration.

Uses

Used in Pharmaceutical Industry:
Albiglutide is used as a therapeutic agent for the treatment of type 2 diabetes. It functions by mimicking the action of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood sugar levels. By enhancing insulin secretion and suppressing glucagon release, albiglutide contributes to better glucose control in patients with type 2 diabetes.
Additionally, due to its long half-life and duration, albiglutide offers the convenience of weekly administration, which may improve patient compliance and overall treatment outcomes.

Clinical Use

GLP-1 receptor agonist: Treatment of type 2 diabetes mellitus

Enzyme inhibitor

This GLP-1 agonist and anti-diabetic drug (MW = 72.9 kDa; CAS 782500- 75-8), marketed as Eperzan? and Tanzeum?, by GlaxoSmithKline (GSK) is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide has a half-life of 4-7 days, commending it for biweekly or weekly administration in the treatment of Type 2 diabetes. The half-life is considerably longer than exenatide (Byetta?) and liraglutide (Victoza?).

Drug interactions

Potentially hazardous interactions with other drugs None known

Metabolism

Albiglutide is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes.